CD40
Tumor necrosis factor receptor superfamily member 5
As of the edition of 20 October 2026, CD40 (tumor necrosis factor receptor superfamily member 5, UniProt P25942) has 16 drugs tested at it and 15 companies on the list, 9 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25942
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 14
- Disease areas
- Cancer; Skin and connective tissue; Immune system; Blood and lymph; Lungs and airways; Digestive system; Hormones; Pregnancy and women's health
- Registered trials of its drugs
- 97
Drugs at this target
| Status | Count |
|---|---|
| Active | 6 |
| Went quiet | 6 |
| Stopped | 4 |
| Total | 16 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sotigalimab | Stopped | Phase 2 | none listed |
| Selicrelumab | Active | Phase 2 | none listed |
| CDX-1140 | Active | Phase 2 | none listed |
| Iscalimab | Stopped | Phase 2 | none listed |
| Dacetuzumab | Stopped | Phase 2 | none listed |
| BI 655064 | Went quiet | Phase 2 | none listed |
| Bleselumab | Went quiet | Phase 2 | none listed |
| PG-102 | Active | Phase 2 | none listed |
| Cd40 ligand | Went quiet | Phase 2 | none listed |
| Giloralimab | Active | Phase 1 | none listed |
| Lucatumumab | Went quiet | Phase 2 | none listed |
| GEN1042 | Active | Phase 2 | none listed |
12 of 16 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Engaged | 6 |
| Total on the list | 15 |
The other 12 companies at CD40
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at CD40, ranked, with the facts behind eachRequest access. Nothing is shown until you do.